SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-249962
Filing Date
2023-10-03
Accepted
2023-10-03 16:31:01
Documents
12
Period of Report
2023-10-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d517569d8k.htm   iXBRL 8-K 26553
  Complete submission text file 0001193125-23-249962.txt   149423

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20231003.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20231003_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20231003_pre.xml EX-101.PRE 11266
6 EXTRACTED XBRL INSTANCE DOCUMENT d517569d8k_htm.xml XML 3360
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 231304281
SIC: 2834 Pharmaceutical Preparations